Page last updated: 2024-12-04

benfluorex

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2318
CHEMBL ID400599
CHEBI ID93826
SCHEMBL ID163648
MeSH IDM0041824

Synonyms (93)

Synonym
2-({1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl}amino)ethyl benzoate
BRD-A22305049-003-05-2
benfluorex ,
ethanol, 2-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]-, benzoate
DIVK1C_000033
KBIO1_000033
2-((alpha-methyl-m-(trifluoromethyl)phenethyl)amino)ethanol benzoate (ester)
ethanol, 2-(alpha-methyl-m-trifluoromethylphenethylamino)-, benzoate
jp 992
minolip
brn 4152887
einecs 245-777-9
mediaxal
benfluramate
phenethylamine, n-(2-hydroxyethyl)-alpha-methyl-m-trifluoromethyl-, benzoate
2-(alpha-methyl-m-trifluoromethylphenethylamino)ethanol benzoate
se 780
benfluorexum [inn-latin]
n-(2-hydroxyethyl)-alpha-methyl-m-trifluoromethylphenethylamine benzoate
SPECTRUM_000272
PRESTWICK2_000367
PRESTWICK3_000367
BSPBIO_002966
NCGC00178369-02
NCGC00178369-01
D07192
23602-78-0
benfluorex (inn/ban)
mediaxal (tn)
BSPBIO_000493
IDI1_000033
MLS001333109
smr000857234
MLS001333110
jp-992
n-(2-benzoyloxyethyl)norfenfluramine
mediator
AB00053576
SPECTRUM5_001421
KBIO2_000752
KBIO3_002186
KBIO2_003320
KBIO2_005888
KBIOGR_001291
KBIOSS_000752
SPBIO_001034
SPECTRUM2_001217
SPECTRUM3_001383
PRESTWICK1_000367
SPBIO_002414
PRESTWICK0_000367
NINDS_000033
SPECTRUM4_000806
BPBIO1_000543
nsc-757396
CHEMBL400599
2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl benzoate
AKOS024319409
HMS2230N21
benfluorex [inn:ban:dcf]
benfluorexum
403fo0nqg3 ,
nsc 757396
unii-403fo0nqg3
HMS3373E17
CCG-220367
SCHEMBL163648
benfluorex [who-dd]
benfluorex [inn]
benfluorex [mi]
DTXSID5048471
benfluorexhydrochloride
se-780
2-[[.alpha.-methyl-m-(trifluoromethyl)phenethyl]amino]ethanol benzoate (ester)
ethanol, 2-(.alpha.-methyl-m-trifluoromethylphenethylamino)-, benzoate
n-(2-hydroxyethyl)-.alpha.-methyl-m-trifluoromethylphenethylamine benzoate
2-((1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl)amino)ethyl benzoate #
phenethylamine, n-(2-hydroxyethyl)-.alpha.-methyl-m-trifluoromethyl-, benzoate
2-(.alpha.-methyl-m-trifluoromethylphenethylamino)ethanol benzoate
s-780
AB00053576_13
DB09022
benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester
CHEBI:93826
SBI-0051587.P002
HMS3713I15
Q421695
BRD-A22305049-003-08-6
benflurorex
2-((1-(3-(trifluoromethyl)phenyl)propan-2-yl)amino)ethyl benzoate
ethanol, 2-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]-, benzoate(ester)
CS-0013373
HY-B1058A

Research Excerpts

Overview

Benfluorex is an amphetamine appetite suppressant derived from fenfluramine. It is approved for the treatment of metabolic syndrome and type 2 diabetes mellitus. BenfluoreX + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin.

ExcerptReferenceRelevance
"Benfluorex is a fenfluramine derivative which has been marketed between 1976 and 2009. "( Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report.
Banfi, C; Baufreton, C; Bruneval, P; Ennezat, PV; Fouquet, O; Giraud, R; Rousselet, MC, 2017
)
2.15
"Benfluorex is an amphetamine appetite suppressant derived from fenfluramine. "( Benfluorex: increasing reports of valve disorders.
, 2010
)
3.25
"Benfluorex is a fenfluramine derivative approved for the treatment of metabolic syndrome and type 2 diabetes mellitus."( Mitral and aortic valvular disease associated with benfluorex use.
Castellant, P; Etienne, Y; Fatemi, M; Frachon, I; Jobic, Y; Quintin-Roué, I, 2011
)
1.34
"Benfluorex is a hypolipidaemic agent with biguanide-like properties. "( Mechanism(s) of the blood glucose lowering action of benfluorex.
Da Tos, V; De Biasi, L; Del Prato, S; Dorella, M; Marescotti, MC; Riccio, A; Tiengo, A; Vigili de Kreutzenberg, S, 1993
)
1.98
"Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin."( Added benfluorex in obese insulin-requiring type 2 diabetes.
Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998
)
1.5
"Benfluorex is a clinical lipid-lowering agent with antihyperglycemic properties. "( Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus).
Bennani, N; El Madani, T; Hadjiisky, P; Marquié, G; Pieraggi, MT; Ravel, D; Seguin, L; Solera, ML, 1998
)
1.99
"Benfluorex is a hypolipidemic agent with biguanide-like properties. "( [Mechanisms of hypoglycemic action of benfluorex].
Da Tos, V; Del Prato, S; Dorella, M; Riccio, A; Vigili de Kreutzenberg, S, 1992
)
2

Effects

Benfluorex has the same adverse effects as those that led to the withdrawal of amphetamine appetite suppressants such as fenfluramine. There is no proven benefit that justifies exposing patients to these risks.

ExcerptReferenceRelevance
"Benfluorex has the same adverse effects as those that led to the withdrawal of amphetamine appetite suppressants such as fenfluramine.There is no proven benefit that justifies exposing patients to these risks."( Benfluorex: increasing reports of valve disorders.
, 2010
)
2.52
"Benfluorex has been withdrawn from the French market in November 2009, after more than 30 years of use. "( [Number of deaths attributable to benfluorex].
Hill, C, 2011
)
2.09
"Benfluorex hydrochloride has known lipid- and glucose-lowering effects. "( Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993
)
3.17
"Benfluorex has both anorectic and metabolic effects that lower body weight and improve insulin sensitivity in obesity and type 2 diabetes."( Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC; Wood, GO, 1997
)
1.29
"Benfluorex has been reported to decrease blood glucose in different dismetabolic conditions, particularly in noninsulin-dependent diabetic (NIDD) patients, but the mechanism of this effect is poorly known. "( Benfluorex and blood glucose control in non insulin-dependent diabetic patients.
Boine, L; Cavallo-Perin, P; Cobelli, C; Estivi, P; Galletti, R; Pacini, G; Pagano, G, 1991
)
3.17

Treatment

Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals. The treatment produced a sharp reduction in food intake which remained suppressed despite recovery toward normal after 2 weeks of treatment.

ExcerptReferenceRelevance
"Benfluorex treatment lowered diastolic and systolic blood pressures and improved glucose tolerance in both age groups."( Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men.
Beer, NA; Beer, RM; Colombo, C; Jakubowicz, DJ; Nestler, JE, 1995
)
1.29
"Benfluorex treatment and pair feeding decreased serum triacylglycerol concentrations by about 50%; there was a preferential loss of triacylglycerols containing longer chain fatty acids in the males, whereas this selectivity was not seen in the females."( Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat.
Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1996
)
1.41
"Benfluorex treatment to some extent prevented the decrease in GLUT4 protein in white and brown adipose tissue and in white muscle associated with diabetes."( Evidence for posttranscriptional regulation of GLUT4 expression in muscle and adipose tissue from streptozotocin-induced diabetic and benfluorex-treated rats.
Camps, M; Castelló, A; Chillarón, J; Furriols, M; Muñoz, P; Palacín, M; Testar, X; Zorzano, A, 1996
)
1.22
"Both benfluorex-treated and pair-fed rats had a significant increase in sensitivity to acetylcholine-induced (nitric oxide-mediated) vascular relaxation."( Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC; Wood, GO, 1997
)
1.03
"Benfluorex-treated animals showed significant decreases in glucose intolerance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, and plasma LDL- and VLDL-cholesterol, with no evidence of aortic atheroma."( Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus).
Bennani, N; El Madani, T; Hadjiisky, P; Marquié, G; Pieraggi, MT; Ravel, D; Seguin, L; Solera, ML, 1998
)
1.27
"Benfluorex treatment caused a substantial increase in the content of GLUT4 protein in white muscle; however, GLUT4 levels in red muscle remained low."( Benfluorex improves muscle insulin responsiveness in middle-aged rats previously subjected to long-term high-fat feeding.
Gumà, A; Muñoz, P; Palacín, M; Sevilla, L; Testar, X; Zorzano, A, 1999
)
2.47
"Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals."( [Mode of action of benfluorex. Recent data].
Brindley, DN, 1992
)
1.33
"The benfluorex treatment produced a sharp reduction in food intake which remained suppressed despite recovery toward normal after 2 weeks of treatment."( Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex.
al-Sieni, AI; Brindley, DN; Hales, P; Russell, JC, 1991
)
0.97
"Treatment with benfluorex was well tolerated; 39% of these patients reported one or more emergent adverse events (compared to 38% on placebo and 43% on metformin) and only two patients suffered a treatment-related, serious adverse event."( Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.
Del Prato, S; Erkelens, DW; Leutenegger, M, 2003
)
0.97

Toxicity

ExcerptReferenceRelevance
" Further studies should be conducted to determine the subsequent course of benfluorex-induced VHD and PAH, and to identify genetic, biological and clinical factors that determine individual susceptibility to developing such adverse effects."( Adverse effects of benfluorex on heart valves and pulmonary circulation.
Andréjak, M; Maréchaux, S; Peltier, M; Szymanski, C; Tribouilloy, C, 2014
)
0.96

Dosage Studied

ExcerptRelevanceReference
" In diabetic patients treated with sulphonylureas and phenformin at low dosage (glibenclamide 5 mg and phenformin 50 mg) it was possible to maintain good glycometabolic control using only the sulphonylurea gliclazide (160 mg/die)."( [Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations].
Benzi, L; Cecchetti, P; Ciccarone, AM; Di Cianni, G; Giannarelli, R; Navalesi, R; Penno, G,
)
0.39
" Statistical analysis of the results from 22 patients showed that there was no significant difference between prothrombin times and anticoagulant dosage in the period when patients were receiving benfluorex and the values recorded during the baseline and follow-up periods."( Co-administration of benfluorex with oral anticoagulant therapy.
Brems, HM; De Witte, P, 1980
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.79430.044717.8581100.0000AID485294
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686979
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1779088Half life in rat plasma2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (152)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (9.87)18.7374
1990's37 (24.34)18.2507
2000's19 (12.50)29.6817
2010's78 (51.32)24.3611
2020's3 (1.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.81 (24.57)
Research Supply Index5.27 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index69.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (12.87%)5.53%
Reviews15 (8.77%)6.00%
Case Studies17 (9.94%)4.05%
Observational3 (1.75%)0.25%
Other114 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00544518]Phase 2240 participants (Anticipated)Interventional2007-10-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]